La investigación se centró en estos órganos linfáticos de personas de distintas edades. Son considerados la “primera línea de ...
INmune Bio (NASDAQ:INMB) on Wednesday filed a prospectus for a mixed shelf offering of up to $250 million. This prospectus is ...
21h
Conversamos en exclusiva con el doctor Jesús San Miguel, especialista en hematología y hemoterapia sobre el tratamiento CAR-T ...
Potential INmune Bio, Inc. ( NASDAQ:INMB) shareholders may wish to note that the Independent Director, Scott Juda, recently ...
INmune Bio is focused on developing drugs for neurology and cancer medicine. Find out why INMB stock is a Buy.
The net proceeds is expected to fund the Company through the readout of the ongoing Phase 2 trial (AD02) in patients with Early Alzheimer’s Disease (AD) using XPro™ and through the metastatic ...
Científicos identificaron las neuronas que regulan la potencia de la respuesta inmune. Específicamente determinaron cuáles son las células cerebrales que dosifican la inflamación/desinflamación durant ...
Clinical-stage immunology company INmune Bio (NASDAQ:INMB) entered into definitive agreements for the sale and purchase of 571,592 shares above market warrant exercise price. Officers, employees and ...
Currently, monoclonal antibodies targeting immune checkpoint proteins are a mainstay of cancer therapy and cancer drug ...
El descubrimiento representa una nueva forma de reactivar el sistema inmunológico para combatir tumores resistentes al ...
In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Inmune Bio (INMB – Research Report), with a ...
Esta estrategia ha desencadenado una fuerte respuesta inmune, según un se recoge en un estudio de investigadores de la ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback